



Universitat de Lleida

Document downloaded from:

<http://hdl.handle.net/10459.1/65513>

The final publication is available at:

<https://doi.org/10.1007/s00213-018-4982-9>

Copyright

(c) Springer Verlag, 2018

[Click here to view linked References](#)

Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia

Mariana I. Holubiec ^{a,1,2}, Juan I. Romero ^{a,1,2}, Juan Suárez ^a, Manuel Portavella ^b, Emilio Fernández-Espejo ^c, Fernando Rodríguez de Fonseca ^{a*}, Eduardo Blanco ^{d*}, Pablo Galeano ^{a,2*}

^a Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Avenida Carlos Haya 82, 29010 Málaga, Spain.

^b Laboratorio de Conducta Animal y Neurociencia, Departamento de Psicología Experimental, Facultad de Psicología, Universidad de Sevilla, C/Camilo José Cela s/n, 41018 Sevilla, Spain.

^c Laboratorio de Neurofisiología y Neurología Molecular, Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Av. Sánchez Pizjuán 4, 41009 Sevilla, Spain.

^d University of Lleida, Lleida Institute for Biomedical Research, Dr. Pifarré Foundation (IRBLleida), Av. Alcalde Rovira Roure 80, 25198 Lleida, Spain.

¹ *These authors contributed equally to this work*

Correspondence should be addressed to: Prof. Dr. Fernando Rodríguez de Fonseca*, UGC de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Avda. Carlos Haya 82, 29010 Málaga, Spain. E-mail address: fernando.rodriguez@ibima.eu, ORCID: 0000-0002-4516-5795; **Prof. Dr. Eduardo Blanco, University of Lleida, Lleida Institute for Biomedical Research, Dr. Pifarré Foundation (IRBLleida), Av. Alcalde Rovira Roure 80, 25198 Lleida, Spain. E-mail address: eduardo.blanco@pip.udl.cat, ORCID: 0000-0003-0357-1151; **Dr. Pablo Galeano**, Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA-CONICET), Av. Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina. E-mail address: pgaleano@leloir.org.ar, ORCID: 0000-0003-4491-2039

² *Permanent address*: Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina.

Acknowledgments

1
2
3 This work was supported by grants from Fundació “La Marató de TV3” (386/C/2011), European
4
5 Regional Development Funds-European Union (ERDF-EU; Subprograma RETICS Red de Trastornos
6
7 Adictivos RD16/0017/0001), Ministerio de Economía y Competitividad and ISCIII (PI16/01689) to
8
9 FRF; Own Plan of the Andalucía TECH, International Campus of Excellence (ICE) to PG, and grants
10
11 to EFE and FRF from Junta de Andalucía, Spain (EFE, group BIO-127; FRF, group BIO-339). JS
12
13 holds a “Miguel Servet II” research contract from the National System of Health, ISCIII, EU-ERDF
14
15 (CPII17/00024). Mariana I. Holubiec is a fellowship holder from Agencia Nacional de Promoción
16
17 Científica y Tecnológica (ANPCyT, Argentina). Eduardo Blanco is an associate professor of the
18
19 Serra-Hunter Programme from the Catalan Government. Juan I. Romero and Pablo Galeano are
20
21 research members from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET,
22
23 Argentina).

24
25 **Conflict of interest:** None
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

1
2 Neonatal anoxia-ischemia (AI) particularly affects the central nervous system. Despite the many
3 treatments that have been tested, none of them has proven to be completely successful.
4
5 Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are acylethanolamides that do not bind
6
7 to CB1 or CB2 receptors and thus they do not present cannabinoid activity. These molecules are
8
9 agonist compounds of peroxisome proliferator-activator receptor alpha (PPAR α), which modulates the
10
11 expression of different genes that are related to glucose and lipid metabolism, inflammation,
12
13 differentiation and proliferation. In the present study, we analyzed the effects that the administration of
14
15 PEA or OEA, after a neonatal AI event, has over different areas of the hippocampus. To this end, 7-
16
17 day-old rats were subjected to AI and then treated with vehicle, OEA (2 or 10 mg/kg) or PEA (2 or 10
18
19 mg/kg). At 30 days of age, animals were subjected to behavioral tests followed by
20
21 immunohistochemical studies. Results showed that neonatal AI was associated with decreased
22
23 locomotion, as well as recognition and spatial memory impairments. Furthermore, these deficits were
24
25 accompanied with enhanced neuroinflammation and astrogliosis, as well as a decreased PPAR α
26
27 expression. PEA treatment was able to prevent neuroinflammation, reduce astrogliosis and preserve
28
29 cognitive functions. These results indicate that the acylethanolamide PEA may play an important role
30
31 in the mechanisms underlying neonatal AI, and it could be a good candidate for further studies
32
33 regarding neonatal AI treatments
34
35
36

37
38 **Keywords:** Neonatal anoxia-ischemia; Palmitoylethanolamide; Oleoylethanolamide;
39
40 Neuroinflammation; Astrogliosis; Memory impairment
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. Introduction

1
2
3 Neonatal hypoxia ischemia (HI) is an event that is usually triggered during birth. Either fetus
4 lung malfunction or modifications in the placental gas exchange can lead to low levels of oxygen
5 (hypoxia or anoxia) or a diminished blood flow (ischemia) in the fetus (Blanco et al. 2015; Carrera
6 2006). Neonatal HI particularly affects the central nervous system (CNS) (Kumar et al. 2007), which is
7 highly susceptible to oxidative stress, in part due to the elevated concentration of fatty acids present
8 in this tissue (Halliwell, 1992). So far, hypothermia has been the only treatment that was able to
9 consistently prevent the neurological damage and sequels associated to neonatal HI (Mishima et al.
10 2004; Sebetseba et al. 2017). Neonatal HI is associated to learning and memory impairments (Blanco
11 et al. 2015; Galeano et al. 2011, 2015; Takada et al. 2016). Mainly, it has shown to cause several
12 cellular and molecular modifications in the hippocampus, including astrogliosis and focal swelling,
13 among others (Blanco et al. 2015; Saraceno et al. 2010, 2012).
14
15
16
17
18
19
20
21
22
23
24

25 The endogenous cannabinoids system (ECS) includes different enzymes responsible for
26 endocannabinoid synthesis, transport and degradation, as well as endocannabinoids and
27 endocannabinoid receptors (Ueda et al. 2013). The ECS is important for its regulation over different
28 neurological and physiological processes, that include neural development, synaptic plasticity, reward
29 processing, learning processes, neurogenesis and embryonic cell fate in the developing brain,
30 through the activation of cannabinoid receptors 1 (CB1) and 2 (CB2) (Ahmad and Laviolette 2017;
31 Alonso-Alconada et al. 2011; Blanco-Calvo et al. 2014; Serrano et al. 2012; Schoch et al. 2018; Ueda
32 et al. 2013; Zhou et al. 2017).
33
34
35
36
37
38
39
40
41
42

43 Endocannabinoids are produced from membrane phospholipids depending on cell demand,
44 and they are soon degraded by the corresponding enzyme. These compounds are divided into two
45 groups of fatty acid derivatives that present specific structures: acylethanolamides (AEs) and
46 monoacylglycerols (MAGs) (Hansen and Diep 2009; Serrano et al. 2012; Ueda et al. 2013). To the
47 date, the further characterized endocannabinoids are arachidonoyethanolamide (AEA, an AE also
48 known as anandamide) and 2-arachidonoyglycerol (2AG, a MAG). AEs are synthesized from
49 glycerophospholipids and degraded by the fatty acid amide hydrolase (FAAH) (Okamoto et al. 2009;
50 Pasquarelli et al. 2015; Ueda et al. 2013). Other ethanolamine and palmitic acid amides such as
51 palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are AEs that share both biosynthetic and
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 degradative pathways with AEA. However, these amides do not bind to CB1 and CB2 and thus they
2 do not present cannabinoid activity (Fu et al. 2003; Scuderi et al. 2011). These molecules have been
3 described as agonist of peroxisome proliferator-activator receptor alpha (PPAR α), which is expressed
4 in microvascular, neuronal and glial tissues, and plays a key role in glucose and lipid metabolism,
5 inflammation, differentiation and proliferation (Cristiano et al. 2005; Xu et al. 2006). Furthermore, this
6 receptor has been shown to play a key role as a neuroprotectant in different disorders (Bhateja et al.
7 2012; Bordet et al. 2006; Moran et al. 2014).

14 In previous works it has been shown that OEA and PEA present neuroprotective effects in
15 cerebral ischemia (Ahmad et al. 2012; Naccarato et al. 2010; Yang et al. 2015; Zhou et al. 2012).
16 Moreover, former studies from our group have shown diminished PPAR α levels in hippocampus and
17 striatum of animals that had been exposed to perinatal asphyxia (Blanco et al. 2015; Holubiec et al.
18 2017). In the present study we aimed to analyze the effect that the administration of both PEA and
19 OEA, after a neonatal anoxic-ischemic (AI) event, has over different areas of the hippocampus. To
20 this purpose, the expression of different markers (Iba-1, GFAP and PPAR α) was studied and an array
21 of behavioral tests was performed.

31 **2. Materials and methods**

34 **2.1. Experimental subjects**

37 Experiments in this study were performed in accordance with the ARRIVE (Animal Research:
38 Reporting of *In Vivo* Experiments) and following the standards disposed by the European Directive
39 2010/63/EU and the Spanish Royal Decree 53/2013 on the protection of animals used for research
40 and other scientific purposes. All experiments (including the used of experimental animals) were
41 approved by the ethic committee "Comité de Ética e Investigación Biosanitaria" of the IBIMA and
42 University of Málaga. Female Sprague Dawley pregnant rats were kept in a vivarium under standard
43 controlled conditions (temperature: 21 ± 2 °C; humidity: 65 ± 5 %; dark/light cycle: 12 h /12 h), and
44 were supplied with ad libitum access to food (Purina chow) and tap water. Twenty-one days after the
45 delivery date, pups were removed from their dams and housed in cages of four animals each under
46 the same standard conditions as mentioned for the pregnant animals. Only male pups were selected
47 to perform the present study.

2.2. Common carotid artery ligation and anoxia procedures

The neonatal anoxia-ischemia model that was used in the present study has been already validated (Lopez-Aguilera et al. 2012; Romero et al. 2015, 2017). Dams were monitored daily in order to determine the exact date of birth of the pups. When the animals were 7 days old (P7), males were selected to be subjected to carotid artery ligation. Pups were anesthetized using a mixture of 40 mg/kg ketamine and 4 mg/kg xylazine in order to also produce analgesia. When the animals were ready they were placed in a heated pad to prevent their body temperature from dropping below 37 °C. The area to be operated on was properly disinfected and an incision was made in order to reach the right common carotid artery. When the artery was free of surrounding tissue it was properly ligated using a 6-0 surgical silk thread. After a recovery period the pups were subjected to a 100 % nitrogen environment at 37 °C for 3 min to induce anoxia. (AI group n = 41). The control group was also subjected to the surgical procedure; however the artery was exposed but not ligated. These animals were not exposed to the anoxia treatment either (Sham group = 42). The mortality rate of the procedure was about of 5 %.

2.3. PEA and OEA treatments

An hour after the artery ligation and nitrogen exposure (or sham procedures) were finished pups were injected intraperitoneally (i.p.) with a DMSO solution [vehicle, n = 9 sham pups (Sham-Veh) and 10 AI pups (AI-Veh)], 2 mg/kg of OEA [n = 7 sham pups (Sham-O2) and n = 7 AI pups (AI-O2)], 10 mg/kg of OEA [n = 9 sham pups (Sham-O10) and n = 9 AI pups (AI-O10)], 2 mg/kg of PEA [n = 7 sham pups (Sham-P2) and n = 7 AI pups (AI-P2)], and 10 mg/kg of PEA [n = 9 sham pups (Sham-P10) and n = 9 AI pups (AI-P10)]. Pups were pseudo-randomly assigned to each group and these were composed by pups from at least three different dams. Twenty-three days after the carotid ligation treatment (or sham procedures), animals were subjected to a battery of behavioral tests and then euthanized and brains collected for immunohistochemistry analysis.

2.4. Behavioral assessment

When rats were 30 days old 7-10 animals from each of the groups were subjected to a number of behavioral tests (Elevated Plus Maze, Open Field, Object Recognition, Morris Water Maze and Passive Avoidance tests). Every animal was subjected to a period of handling prior the beginning of the behavioral assessment (five minutes per day during three consecutive days). The whole set of

1 tests was carried out during the 12 h of light and soft background noise was provided throughout the
2 whole process. Training sessions were recorded (JVC Everio GZHD620 camcorder) and analyzed
3 using a computerized video-tracking system (ANY-maze, Stoelting Co., Wood Dale, IL) or with the
4 ethological software J WatcherV1.0.
5
6

7 8 **2.3.1. Elevated plus maze test** 9

10
11 The elevated plus maze (EPM) test was carried out in a plus shaped device consisting of a
12 central platform (11 × 11 cm) and four equally long arms: two open (50 × 11 × 0.25 cm) arms and two
13 arms surrounded by walls (50 × 11 × 40 cm) (Galeano et al. 2015). The device was set 100 cm above
14 the floor. The apparatus was evenly illuminated with an intensity measured in open arms of 85–90 lux.
15 For each trial the animal was placed in the middle of the device facing one of the open arms. Animals
16 were left to explore the apparatus for 5 min. An entry to an arm was counted when the rat set all four
17 paws into one arm. Total distance covered, number of times the animal entered a closed arm,
18 percentage of open arm entries (open arm entries/total entries × 100) and percentage of time spent in
19 open arms (time spent in open arms/300 × 100) were recorded.
20
21
22
23
24
25
26
27
28
29

30 **2.3.2. Open field test** 31

32
33 For the open field (OF) test an evenly illuminated black arena was utilized (60 × 60 cm and 40
34 cm high) (Galeano et al. 2015). In order to delimit the central and most illuminated area (70 lux) of the
35 arena an imaginary square of 30 × 30 cm was drawn over the image of the apparatus during the data
36 analysis. Animals were carefully set in the apparatus and left to explore it for 10 min. An animal was
37 considered to be in the central area when its four paws were on the delimited 30 x 30 cm square.
38 Distance covered, number of rears, number of entries and time spent into the central area were
39 recorded in two time bins of 5 min each.
40
41
42
43
44
45
46
47

48 **2.3.3. Novel object recognition test** 49

50
51 The novel object recognition test (NORT) was carried out 24 h following the OF, using the
52 same arena. NORT is a widely employed and validated test to assess recognition memory (Ennaceur
53 2010; Ennaceur and Delacour 1988). During the test animals were set in the arena where two
54 identical objects were placed. Rats were allowed to explore the apparatus and the objects for 5 min
55 (sample trial). This trial was followed by a period (1 h) in which animals were returned to their cages.
56
57
58
59
60
61
62
63
64
65

1 Rats were then returned once more to the arena and were presented with one familiar object and a
2 novel one. Animals were given 3 min to explore the objects and then returned to their cages (retention
3 trial). The apparatus was evenly illuminated at approximately 70 lux and the device and the objects
4 were thoroughly clean between animals. All possible location or object combinations were employed
5 to prevent bias due to a preference for a particular object or specific location. Animals were
6 considered to be exploring an object when their snout was directed towards it at a distance of 2 cm or
7 less. Discrimination index (d1) and ratio (d2) scores were calculated using the following formulas: $d1$
8 = $\frac{tn - tf}{tn + tf}$, and $d2 = \frac{tn - tf}{tn + tf}$, where tn is the amount of time that rats spend exploring the novel
9 object and tf is the amount of time rats explored the familiar object.
10
11
12
13
14
15
16
17
18

19 **2.3.4. Morris water maze test**

20
21 For the Morris water maze (MWM) a black steel tank (180 cm diameter; 60 cm deep) filled
22 with water at 22 ± 1 °C and a translucent circular platform were used (Galeano et al. 2011, 2015).
23 Different visual cues were located on the walls surrounding the maze and the whole setting was
24 indirectly illuminated. The tank was divided by the operators in four equal quadrants and the platform
25 was set in the middle of one of the quadrants. According to each quadrant, four starting positions
26 were determined. Latency to platform, distance to platform and swim speed were registered during
27 spatial learning training. In the probe trial, the platform was removed and the percentage of time spent
28 in each quadrant and the numbers of crossings over a circular area (with a diameter larger than
29 platform diameter) located on the previous platform position were recorded.
30
31
32
33
34
35
36
37
38
39

40 In the cued learning phase, the surrounding visual cues were covered with a black curtain and
41 the platform was set 2 cm above water level with a flag attached to it. Eight cued learning trails were
42 performed during two day (four each day). The location of the platform and the starting point were
43 modified for each trial. If after 60 s the animal had not found the platform it was gently guided to it and
44 left there for 15 s. To assess spatial learning and reference memory the black curtain was removed
45 and the visual cues were available while the platform was set under water (2 cm below the water
46 surface). The test consisted of four trials each day, performed over the period of 6 days. The animal
47 was released from one of the starting positions and it was left to explore the maze looking for the
48 hidden escape platform (the platform remained in the same location for all the trails). If the animal was
49 unable to find the platform after 60 s it was guided to it and left there for 15 s. During each trial the
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 starting position was changed and the sequence used varied along the 6 days of the test. Reference
2 memory was assessed 24 h after the last learning trail with a probe trial of 60 s. For this probe trial the
3 animal was released from a novel starting position and the platform was removed from the maze.
4
5

6 **2.3.5. Passive avoidance**

7
8
9 The passive avoidance test was used to assess associative memory (Deacon et al. 2002). The
10 device consisted of a box (60 cm × 60 cm × 40 cm) divided in two. The resulting compartments were
11 both 30 cm long and separated by a door that opened sliding into the floor. One of the compartments
12 was made of white plastic and well illuminated. The second compartment was dim and made of dark,
13 electrifiable metal. During the acquisition phase the rat was placed in the light compartment and it was
14 allowed to freely explore de devise. The moment the animal crossed into the black compartment it
15 received a mild foot shock (1.2 mA, 2 s duration) and it was promptly removed from the device. One
16 hour later, the retention trial took place and the rat was again placed in the white compartment and
17 was left to freely explore the entire apparatus during a maximum of 10 min (no foot shock was
18 delivered once it entered the dark compartment). The ratio between the latency of the rat to move into
19 the dark compartment in the retention trial (T2) and in the training sessions (T1) was taken as a
20 measure of associative memory retention (T2/T1) (Deacon et al. 2002).
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **2.4. Tissue processing**

35
36
37 After the behavioral assessment was finished, 4-5 randomly chosen rats per group were
38 administered with a mixture of 40 mg/kg ketamine and 4 mg/kg xylazine and subjected to an
39 intracardiac perfusion, firstly with saline solution (0.9 % Sodium Chloride) with 1 % (v/v) heparin in
40 order to clean the tissues, and finally with cold 4 % formaldehyde solution (freshly made from
41 paraformaldehyde; Sigma-Aldrich, St. Louis, MO, USA). When the tissue was properly fixated the
42 brain was carefully extracted and post fixed in formaldehyde solution for 2 h at 4 °C. Finally, 40- μ m-
43 thick coronal sections were obtained from each brain and they were properly stored in a 0.002 %
44 (w/v) NaN₃ solution at 4 °C.
45
46
47
48
49
50
51
52
53

54 **2.5. Immunohistochemical procedures**

55
56
57 The presence of markers related to neuroinflammation, astrogliosis and the expression of
58 PPAR α were assessed using immunohistochemistry. For this purpose sections from each group were
59
60
61
62
63
64
65

1 placed in separate wells in a 24 well plate. Samples were washed 5 times for 10 min using 0.1 M
2 phosphate buffer solution with 0.5 % Tween 20 (PBS-T), at room temperature (RT) in order to
3 properly eliminate the formaldehyde that was used as a fixative agent. To block the endogenous
4 peroxidase, sections were incubated with 30 % H₂O₂ in PBS during 30 min at RT. Samples were then
5 washed 5 times for 10 min with PBS-T and unspecific antigens were blocked incubating the sections
6 in 4 % BSA (Bovine Serum Albumin), diluted in PBS-T, for 1 h at RT. Afterwards samples were
7 washed 5 times for 10 min with PBS-T and then incubated with the corresponding primary antibody
8 [rabbit anti-Iba-1 (1:1000, Wako, Osaka, Japan; cat. no. 019-19741; mouse anti-GFAP (1:500,
9 G3893, Sigma; rabbit anti-PPAR α (1:100, P11120812, Fitzgerald)] over night at 4 °C. The following
10 day samples were washed 5 times for 10 min using PBS-T and subsequently incubated with
11 horseradish-peroxidase (HRP) biotinylated secondary antibody (donkey anti-rabbit IgG, 5356499, GE
12 Healthcare; goat anti-mouse IgG, 125K6063, Sigma) for 2 h at RT. Once the two hours had elapsed,
13 samples were again washed 5 times for 10 min with PBS-T and incubated with ABC (Avidin-Biotin
14 complex) solution (1:1000; ExtrAvidin peroxidase, Sigma, St Louis, MO, USA) for 1 h in darkness at
15 RT. The ABC solution was washed 5 times for 10 min using PBS-T. Finally the signal was detected
16 using 0.05 % diaminobenzidine (DAB; Sigma) diluted in PBS containing 0.03 % H₂O₂. Sections were
17 then washed several times using running water, mounted on slides treated with poly-L-lysine solution
18 (Sigma) and subjected to a process of dehydration (increasing ethanol concentration followed by
19 xylene). Samples were covered with cover slips using Eukitt mounting medium (Kindler GmbH & Co.,
20 Freiburg, Germany). After they were dry, samples were observed using an Olympus BX41
21 Microscope coupled with an Olympus DP70 digital camera (Olympus, Germany) or an Olympus BX60
22 microscope coupled to Olympus DP71 digital camera (Olympus, USA). All the photographs were
23 taken under the same conditions of light and brightness/contrast.

2.6. Immunohistochemical quantification

24 Four to seven coronal sections from Bregma levels -3.14 to -4.30 mm (dorsal hippocampus)
25 (Paxinos 2007), from each animal, were selected and employed for immunohistochemical analysis.
26 Quantification was carried out using the “Cell counter” plug in tool from Image J software (NIH, USA).
27 Images were changed to binary code and the area of interest delimited. For Iba-1 and GFAP
28 quantification, 0.08 mm² squares were set and distributed so that each area of the hippocampus
29 studied (CA1, CA3 and DG) was properly represented, while 0.02 mm² squares were employed in the
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 case of PPAR α . The number of positive cells was manually determined in each square and averaged
2 to determine the number of cells per mm². Quantifications were made by experimenters blinded to
3 treatments.
4

5 6 **2.7. Statistics analysis**

7
8 Behavioral and immunohistochemical data were analyzed by one or two-way ANOVA tests,
9 followed by Tukey's post hoc multiple comparison tests. Moreover, one sample t-tests were employed
10 when it was required. A probability equal or less than 5 % was accepted as statistically significant and
11 always two-sided probabilities were reported. Data are expressed as mean \pm SEM.
12
13
14
15
16
17

18 **3. Results**

19 20 **3.1. Neonatal anoxia-ischemia reduces exploratory activity without modifying anxiety-like** 21 **behaviors in the EPM and OF tests**

22 23 **3.1.1. Elevated plus maze test**

24
25
26
27
28 When the distance covered was analyzed, a two-way ANOVA test revealed that the main factor
29 Postnatal condition was significant ($F_{(1, 73)} = 40.7, p < 0.001$), while neither the main factor Treatment
30 nor the interaction Postnatal condition x Treatment were significant ($F_{(4, 73)} = 1.4, p = \text{n.s.}; F_{(4, 73)} < 1, p$
31 $= \text{n.s.}$). Similarly, in the case of closed arms entries, the main factor Postnatal condition was
32 significant ($F_{(1, 73)} = 16.2, p < 0.001$), while neither the main factor Treatment nor the interaction
33 Postnatal condition x Treatment were significant ($F_{(4, 73)} < 1, p = \text{n.s.}; F_{(4, 73)} < 1, p = \text{n.s.}$). These
34 results indicate that rats that were subjected to anoxia-ischemia, regardless of the treatment received,
35 covered a significantly lower distance and visited significantly fewer times the closed arms in
36 comparison with sham groups (see Fig. 1A-B). Regarding anxiety-related behaviors, none of the
37 groups differed neither in the percentage of open arms entries nor in the percentage of time in open
38 arms (Percentage of open arms entries: Postnatal condition, $F_{(1, 73)} < 1, p < \text{n.s.};$ Treatment, $F_{(4, 73)} < 1,$
39 $p = \text{n.s.};$ Postnatal condition x Treatment, $F_{(4, 73)} < 1, p = \text{n.s.}$ Percentage of time in open arms:
40 Postnatal condition, $F_{(1, 73)} < 1, p = \text{n.s.};$ Treatment, $F_{(4, 73)} < 1, p = \text{n.s.};$ Postnatal condition x
41 Treatment, $F_{(4, 73)} < 1, p = \text{n.s.}$) (see Fig. 1C-D).
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 **3.1.2. Open field test**

58
59
60
61
62
63
64
65

Two-way mixed ANOVA test revealed that the main factors Group and Time, and the interaction Group x Time were all significant ($F_{(9, 146)} = 4.4, p < 0.001$; $F_{(1, 146)} = 132.4, p < 0.001$; $F_{(9, 146)} = 3.2, p = 0.001$, respectively), in the case of distance covered. Post-hoc multiple comparison Tukey tests showed that rats subjected to anoxia-ischemia covered a significantly lower distance than sham groups during the first five minutes (see Fig. 2A). All the groups significantly reduced their distance covered to the same levels during the second five minutes compared with the first five minutes, indicating that every group showed a normal habituation response (see Fig. 2A). When the number of rears was analyzed, the two-way ANOVA tests revealed that the main factors Groups and Time were significant ($F_{(9, 146)} = 2.7, p = 0.005$; $F_{(1, 146)} = 11.2, p = 0.001$, respectively), while the interaction Group x Time was not ($F_{(9, 146)} < 1, p = n.s.$). These results indicate that rats subjected to anoxia-ischemia displayed a significantly lower number of rears across the entire test compared with sham groups and that all groups showed a significantly lower number of rears during the second five minutes than during the first five minutes (see Fig. 2B). Finally, none of the groups presented differences in anxiety-related behaviors (Entries into the center: Group, $F_{(9, 146)} = 1.6, p = n.s.$; Time, $F_{(1, 146)} = 2.1, p = n.s.$; Group x Time, $F_{(9, 146)} < 1, p = n.s.$ Time in central area: Group, $F_{(9, 146)} < 1, p = n.s.$; Time, $F_{(1, 146)} = 1.1, p = n.s.$; Group x Time, $F_{(9, 146)} < 1, p = n.s.$) (see Fig. 2C-D).

3.2. Palmitoylethanolamide prevents cognitive deficits that follow to neonatal anoxia-ischemia

3.2.1. Novel object recognition test

One-sample t-tests revealed that in groups of rats subjected to anoxia-ischemia, except in the case of AI-P10 group, discrimination index (d1) and discrimination ratio (d2) did not differ from a hypothetical 0 value (d1. AI-Veh: $t = 0.4, d.f. = 8, p = n.s.$; AI-O2: $t = 0.8, d.f. = 6, p = n.s.$; AI-O10: $t = 0.6, d.f. = 8, p = n.s.$; AI-P2: $t = 0.5, d.f. = 6, p = n.s.$ d2. AI-Veh: $t = 0.5, d.f. = 8, p = n.s.$; AI-O2: $t = 0.6, d.f. = 6, p = n.s.$; AI-O10: $t = 0.4, d.f. = 8, p = n.s.$; AI-P2: $t = 0.2, d.f. = 6, p = n.s.$) (see Fig. 3A-B). On the other hand, sham groups and the AI-P10 group showed significantly higher d1 and d2 than the hypothetical 0 value, meaning that they spent more time exploring the novel object than the familiar one (d1. Sham-Veh: $t = 3.5, d.f. = 9, p = 0.006$; Sham-O2: $t = 3.3, d.f. = 6, p = 0.013$; Sham-O10: $t = 3.4, d.f. = 8, p = 0.008$; Sham-P2: $t = 5.3, d.f. = 6, p = 0.002$; Sham-P10: $t = 14.7, d.f. = 8, p < 0.001$.; AI-P10: $t = 5.0, d.f. = 8, p = 0.002$. d2. Sham-Veh: $t = 4.6, d.f. = 9, p = 0.002$; Sham-O2: $t = 3.4, d.f. = 6, p = 0.012$; Sham-O10: $t = 4.2, d.f. = 8, p = 0.002$; Sham-P2: $t = 9.7, d.f. = 6, p < 0.001$; Sham-P10: $t = 14.7, d.f. = 8, p < 0.001$.)

= 9.7, $d.f. = 8$, $p < 0.001$; AI-P10: $t = 5.6$, $d.f. = 8$, $p = 0.001$) (see Fig 3A-B). In this test, treatment with 10 mg/kg of PEA prevented the recognition memory deficit showed by AI groups.

3.2.2. MWM test: cue learning

To analyze the performance of animals during the cue learning phase, the latency to reach the visible platform was used as the dependent variable. Two-way ANOVA test revealed that the main effect of Day was significant ($F_{(1, 146)} = 50.8$, $p < 0.001$), while neither the main effect of Group nor the interaction Day x Group were ($F_{(9, 146)} < 1$, $p = n.s.$ for both cases) (see Fig. S1). These results mean that all groups significantly reduced their escape latency from one day to another, indicating the absence of visual or motor impairments and a similar level of motivation between the groups to solve the task.

3.2.3. MWM test: spatial learning and reference memory

To evaluate spatial memory, the dependent values latency to platform, distance to platform and swim speed were analyzed by two-way ANOVA tests. Results indicated that, in the three cases, the main factor Day was significant (Latency: $F_{(5, 438)} = 92.4$, $p < 0.001$; Distance: $F_{(5, 438)} = 115.3$, $p < 0.001$; Speed: $F_{(5, 438)} = 33.5$, $p < 0.001$), while neither the main factor Group nor the interaction Group x Day were significant (Group: Latency, $F_{(9, 438)} < 1$, $p = n.s.$; Distance: $F_{(9, 438)} = 1.1$, $p = n.s.$; Speed, $F_{(9, 438)} < 1$, $p = n.s.$ Group x Day: Latency, $F_{(45, 438)} < 1$, $p = n.s.$; Distance: $F_{(45, 438)} < 1$, $p = n.s.$; Speed, $F_{(45, 438)} < 1$, $p = n.s.$). These results show that all groups, regardless of treatment, significantly reduced their latency, distance and swim speeds at the same rate across days of learning (see Fig. 4A-C).

When time spent in the target quadrant (the quadrant where the platform was located during the spatial learning phase) was analyzed during the probe trial, one-sample t-tests revealed that groups of rats subjected to anoxia-ischemia, except the AI-P10 group, spent a not significantly different percentage of time than expected by chance in this area (25 %, dashed line) (AI-Veh: $t = 1.0$, $d.f. = 8$, $p = n.s.$; AI-O2: $t = 1.3$, $d.f. = 6$, $p = n.s.$; AI-O10: $t = 1.6$, $d.f. = 8$, $p = n.s.$; AI-P2: $t = 1.3$, $d.f. = 6$, $p = n.s.$) (see Fig. 5A). By contrast, sham groups, regardless of treatments, and the AI-P10 group spent significantly higher percentages of time in the target quadrant than expected by chance (Sham-Veh: $t = 5.8$, $d.f. = 9$, $p < 0.001$; Sham-O2: $t = 4.2$, $d.f. = 6$, $p = 0.005$; Sham-O10: $t = 8.8$, $d.f. = 8$, $p < 0.001$; Sham-P2: $t = 5.1$, $d.f. = 6$, $p = 0.002$; Sham-P10: $t = 8.3$, $d.f. = 8$, $p < 0.001$; AI-P10: $t = 5.3$, $d.f.$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

= 8, $p < 0.001$) (see Fig. 5A). A similar pattern of results was obtained when the numbers of crossings over a circular area larger than the platform area were analyzed. The two-way ANOVA test indicated that the main factor Postnatal condition was significant ($F_{(1, 73)} = 29.4$, $p < 0.001$), while neither the main factor Treatment nor the interaction Postnatal condition x Treatment were significant ($F_{(4, 73)} = 1.9$, $p = \text{n.s.}$; $F_{(4, 73)} = 1.7$, $p = \text{n.s.}$, respectively). Although the interaction Postnatal condition x Treatment did not reach a significant level, post-hoc multiple comparison Tukey tests showed that groups of rats subjected to ischemia-anoxia crossed the circular area significantly less times compared with sham and AI-P10 groups (see Fig. 5B). These results indicate that anoxia-ischemia was associated with a spatial reference memory deficit that was prevented by the treatment with palmitoylethanolamide at a dose of 10 mg/kg.

3.2.4. Passive avoidance test

A two-way ANOVA test to analyze the retention index (T2/T1) showed that neither the main factor Postnatal condition nor the main factor Treatment nor the interaction Postnatal condition x Treatment were significant ($F_{(1, 73)} < 1$, $p = \text{n.s.}$; $F_{(4, 73)} < 1$, $p = \text{n.s.}$; $F_{(4, 73)} < 1$, $p = \text{n.s.}$, respectively) (see Fig. S2). This result shows that retention index did not differ among groups, indicating that associative memory was affected neither by anoxia-ischemia nor by treatment with OEA or PEA.

3.3. Hippocampal neuroinflammation induced by neonatal anoxia-ischemia is prevented by palmitoylethanolamide administration

When the number of Iba-1 positive cells were analyzed in the CA1 hippocampal area, a two-way ANOVA test revealed that the main factors Postnatal condition (Sham and AI) and Treatment (Veh, O2, O10, P2, P10) and the interaction Postnatal condition x Treatment were all significant ($F_{(1, 33)} = 103.9$, $p < 0.001$; $F_{(4, 33)} = 7.7$, $p < 0.001$; $F_{(4, 33)} = 3.0$, $p = 0.031$, respectively). Post-hoc multiple comparisons Tukey tests indicated that all groups of rats submitted to neonatal anoxia-ischemia, but the group administered with 10 mg/kg of PEA, showed a significantly higher number of Iba-1 positive cells compared with sham groups (see Fig 6 and Fig. S3). Moreover, AI-P10 group showed a similar number of Iba-1 positive cells compared with sham groups (see Fig 6 and Fig. S3). Finally, it was observed that treatment with OEA (2 or 10 mg/kg) or PEA (2 or 10 mg/kg) had no effect on the number of Iba-1 positive cells among sham groups (see Fig 6 and Fig. S3).

1 Similarly to what had been seen in the hippocampal CA1 area, two-way ANOVA tests revealed
 2 that the main factors Postnatal condition and Treatment and the interaction Postnatal condition x
 3 Treatment were all significant when the number of Iba-1 positive cells were analyzed in CA3 and DG
 4 areas (CA3: $F_{(1, 33)} = 156.0, p < 0.001$; $F_{(4, 33)} = 13.9, p < 0.001$; $F_{(4, 33)} = 3.7, p = 0.013$, respectively;
 5 DG: $F_{(1, 33)} = 94.3, p < 0.001$; $F_{(4, 33)} = 11.5, p < 0.001$; $F_{(4, 33)} = 16.9, p < 0.001$, respectively). Post-hoc
 6 analysis also indicated that, in both hippocampal areas, the number of Iba-1 positive cells was
 7 significantly higher in the AI groups compared with sham groups, except in the case of the AI-P10
 8 which showed a similar number of Iba-1 positive cells to sham groups (see Fig 6 and Fig. S3). Finally,
 9 neither in the CA3 area nor in the DG area, sham groups differed in their number of Iba-1 positive
 10 cells (see Fig 6 and Fig. S3).
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20

21 **3.4. Neonatal anoxia-ischemia induces an astrogliosis response that is partially reverted by** 22 **palmitoylethanolamide treatment** 23

24
 25 To analyze the number of GFAP positive cells in the three areas of the hippocampus studied
 26 (CA1, CA3 and DG), two-way ANOVA tests were performed and results revealed that the main factor
 27 Postnatal condition and the interaction Postnatal condition x Treatment were both significant (CA1:
 28 $F_{(1, 33)} = 97.3, p < 0.001$; $F_{(4, 33)} = 4.3, p = 0.007$, respectively. CA3: $F_{(1, 33)} = 112.4, p < 0.001$; $F_{(4, 33)} =$
 29 $3.6, p = 0.014$, respectively. DG: $F_{(1, 33)} = 69.8, p < 0.001$; $F_{(4, 33)} = 3.1, p = 0.029$, respectively). The
 30 main factor Treatment was not significant in any of the three hippocampal areas (CA1: $F_{(4, 33)} = 1.7, p$
 31 $= \text{n.s.}$ CA3: $F_{(4, 33)} = 1.0, p = \text{n.s.}$ DG: $F_{(4, 33)} = 1.6, p = \text{n.s.}$).
 32
 33
 34
 35
 36
 37
 38
 39

40 In the CA1 area, the analyses of simple effects by post-hoc Tukey tests indicated that AI
 41 groups, except the AI-P10 group, showed a significantly higher number of GFAP positive cells
 42 compared with sham groups (see Fig 7 and Fig. S4). The AI-P10 showed a number of GFAP positive
 43 cells that were not significantly different in comparison with sham groups and the AI-P2 group (see
 44 Fig 7 and Fig. S4). In the CA3 area, AI-Veh, AI-O2, AI-O10 and AI-P2 showed a significantly higher
 45 number of GFAP positive cells compared to sham group, while AI-P10 showed a significantly higher
 46 number of GFAP positive cells in comparison with the Sham-Veh group and significantly lower
 47 number compared with AI-Veh and AI-O10 groups (see Fig 7 and Fig. S4) Finally, in the DG, AI
 48 groups, except for the AI-P10 group, showed a significantly higher number of GFAP positive cells
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65

1 compared with the sham groups, while the AI-P10 group did not significantly differed from the sham
2 group and the remaining AI groups in the number of GFAP positive cells (see Fig 7 and Fig. S4).
3

4 3.5. Neonatal anoxia-ischemia is associated with a reduced PPAR α expression

5
6
7 Two-way ANOVA tests revealed that the main effect of Postnatal condition was significant in all
8 hippocampal areas when the number of PPAR α was analyzed (CA1: $F_{(1, 33)} = 12.5$, $p = 0.01$. CA3: $F_{(1,$
9 $33)} = 16.5$, $p < 0.001$. DG: $F_{(1, 33)} = 24.5$, $p < 0.001$), while the main effect of Treatment and the
10 interaction Postnatal condition x Treatment did not reach significance levels (Treatment: CA1: $F_{(4, 33)} =$
11 1.2 , $p = \text{n.s.}$; CA3: $F_{(4, 33)} = 1.3$, $p = \text{n.s.}$; DG: $F_{(4, 33)} = 2.4$, $p = \text{n.s.}$ Postnatal condition x Treatment:
12 CA1: $F_{(4, 33)} < 1$, $p = \text{n.s.}$; CA3: $F_{(4, 33)} < 1$, $p = \text{n.s.}$; DG: $F_{(4, 33)} < 1$, $p = \text{n.s.}$). Overall, statistical results
13 indicate that AI groups, regardless of the treatment received, showed a significantly lower number of
14 PPAR α positive cells compared with sham groups (see Fig 8 and Fig. S5).
15
16
17
18
19
20
21
22
23

24 4. Discussion

25
26
27 In the present work we studied the potential neuroprotective effects of PEA and OEA on the
28 hippocampus of animals exposed to neonatal AI. For this purpose, an array of behavioral tests and
29 immunohistochemical analysis were performed. In the EPM and OF tests we were able to observe
30 that animals exposed to AI showed a lower response to novelty, while no changes in anxiety-like
31 behaviors were detected. Furthermore, recognition and spatial reference memory impairments were
32 detected in NORT and MWM tests. These memory deficits were prevented by PEA treatment, while
33 OEA administration had no detectable effects. In addition, neonatal AI was associated with an
34 increased number of Iba-1 and GFAP positive cells in the hippocampus, a critical area for memory
35 processing and especially vulnerable to AI (Dai et al. 2017; Zhu et al. 2018). These neurobiological
36 alterations could be, in part, responsible for the cognitive deficits observed, since PEA treatment was
37 also able to prevent neuroinflammation and reduce astrogliosis. Although the neuroprotective effects
38 of PEA have been studied in animal models of brain injury (Ahmad et al. 2012; D'Agostino et al. 2012;
39 Esposito et al. 2012; Schomacher et al. 2008; Scuderi et al. 2018), as far as we know this is the first
40 time that the neuroprotective properties of PEA are reported in a neonatal model of AI.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 4.1. Neonatal AI is associated with reduced novelty response but not with anxiety-related 57 behaviors 58

1 During the EPM and OF tests we found that animals subjected to AI present a lower number of
2 entries to the closed arms (locomotion indicator) as well as a decrease in the total distance covered.
3
4 This effect in locomotion could be attributed to a decrease in the response to novelty since in the OF
5
6 we only observed this change in locomotion during the first 5 min of the test, while every group
7
8 presented a normal response to habituation. We, as well as others, have already observed this lower
9
10 curiosity/motivation to explore novel environments in another model of hypoxia-ischemia (Galeano et
11
12 al. 2011; Strackx et al. 2010), which suggests that this effect could be related to underlying brain
13
14 processes altered by oxygen deprivation rather than other mechanisms triggered by a specific animal
15
16 model.

17
18 It is important to note that, unlike other authors (Ming-Yan et al. 2012; Sedláčková et al. 2014),
19
20 we did not find changes in anxiety-related behaviors. However, this is consistent with previous results
21
22 from our group in another model of global hypoxia-ischemia (Galeano et al. 2011). We could then
23
24 hypothesize that these discrepancies may be related to intrinsic differences between animal models
25
26 of neonatal ischemia. Since the model employed in the present work has been recently validated,
27
28 effects such as this should be noted for further studies.

31 **4.2. PEA treatment prevents memory impairments induced by neonatal AI**

32
33
34 Animals exposed to AI showed recognition and spatial reference memory impairments, while
35
36 associative memory was altered neither by AI nor by pharmacological treatments. Previous works
37
38 have already found an association between alterations in both NORT and MWM tests and AI (Almli et
39
40 al. 2000; Barros et al. 2009; Balduini et al. 2000; Cechetti et al. 2010; Cunha-Rodrigues et al. 2018;
41
42 Domnick et al. 2015; Griva et al. 2017; Pereira et al. 2007). For example, Cunha-Rodrigues et al.
43
44 (2018) found that pups whose mothers had been subjected to uterine artery ligation showed a
45
46 recognition memory deficit concomitant with loss of hippocampal neurons. Moreover, Domnick et al.
47
48 (2015) observed similar results in 2-day-old rat pups subjected to common carotid artery ligation.
49
50 Regarding spatial memory, Griva et al. (2017) observed that animals subjected to left common carotid
51
52 artery ligation followed by 60 min of hypoxia (8% O₂) showed an impaired performance in the MWM.
53
54 Similarly, Cechetti et al. (2010) had already found that animals exposed to bilateral occlusion of the
55
56 common carotid arteries (2VO) present deficits in spatial memory. In the present work, we were able
57
58 to observe that treatment with 10 mg/kg of PEA, administered one hour after AI, prevented
59
60
61
62
63
64
65

1 recognition and reference memory deficits. So far, exogenous administration of PEA has shown to be
2 capable of preventing memory deficits in animal models of Alzheimer's disease (D'Agostino et al.
3 2012; Scuderi et al. 2014, 2018). Regarding associative memory, similarly to what was reported by
4 Balduini et al. (2000), we did not observe differences between sham and AI groups, suggesting that
5 AI has no effects on this type of memory. This results extent the previously observed neurobehavioral
6 beneficial effects of PEA to an ischemia model, and suggest that PEA could be used as a potential
7 treatment against memory impairments induced by different types of brain injuries.
8
9

10 **4.3. Neuroinflammation and astrogliosis induced by AI is partially prevented by PEA treatment**

11
12 In the present work we observed a decrease in PPAR α levels in animals subjected to AI,
13 which is consistent with previous results from our group (Blanco et al. 2015; Holubiec et al. 2017).
14 Furthermore, the results obtained in the present study show that there is an increase in
15 neuroinflammation (Iba-1) and astrogliosis (GFAP) in animals subjected to AI.
16

17
18 It has already been shown that AI leads to inflammation in different parts of the CNS (Driscoll
19 et al. 2018). During recent years the role that microglia plays in disorders of the CNS has been
20 thoroughly studied (Crews et al. 2017; Salter and Stevens 2017). Microglia has been shown to be
21 involved in different processes such as regulation of embryonic vasculogenesis, secretion of trophic
22 factors, immuno-surveillance, oligodendrogenesis and neurogenesis (Mallard et al. 2018). It has been
23 observed that neuroinflammation due to hypoxia-ischemia plays a key and deleterious role in this event
24 (Galinsky et al. 2018). The production of different factors such as IL-18, Caspase-1 and TGF- β has
25 been proven to be related to damages caused by microglia in animals exposed to AI (Chen et al.
26 2018; Mallard et al. 2018). Cunha-Rodrigues et al. (2018) has described oligodendrocyte loss,
27 astrogliosis and neuronal death due to HI. It has also been shown that animals subjected to
28 hypoxemia present astrogliosis 6 months post-injury (Davies et al. 2018). Furthermore, it has been
29 previously observed that neuroinflammation and astrogliosis hold a close relation to deficits in
30 recognition memory (Cunha-Rodrigues et al. 2018; Liaury et al. 2014) and spatial memory (Mirahmadi
31 et al. 2017; Pei and Sun 2018). Liaury et al. (2014) has found that microglial activation correlates with
32 schizophrenia-like behaviors. Thus, we propose that the neuroinflammation and astrogliosis that we
33 observed after AI could be responsible, in part, of the memory deficits that followed AI.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Regarding the treatment with PEA, it has already been demonstrated that this ethanolamide
2 reduces neuroinflammation and presents a neuroprotective activity in rodents (Di Marzo and Skaper
3 2013; Petrosino and Di Marzo 2017; Sayd et al. 2014; Scuderi et al. 2014). For instance, in a rat
4 model of Alzheimer's disease induced by the administration of intrahippocampal beta amyloid 1-42, a
5 later treatment with PEA proved to be effective reducing neuroinflammation and exerting
6 neuroprotective actions (Scuderi et al. 2014). Furthermore, PEA was shown to promote neuronal
7 survival in the hippocampus, normalize astrocytic function and balance glutamatergic transmission,
8 thus leading to an improvement in memory impairments (Scuderi et al. 2018). In the present study we
9 show that the increase in neuroinflammation and astroglyosis were partially reverted in animals
10 treated with 10 mg/kg of PEA. Since PEA also showed a preventive effect regarding the memory
11 deficits observed, we propose that these two phenomena may be closely related.
12
13
14
15
16
17
18
19
20
21

22 **5. Conclusions**

23
24
25 In the present work we show that AI is associated with recognition and spatial memory
26 impairments in a new model of neonatal AI. We have also found that these memory deficits may be
27 related to neuroinflammation and astrogliosis in the hippocampus, since PEA treatment partially
28 reversed this alterations and it was able to prevent memory impairments. Although PEA has shown to
29 posses neuroprotective effects in different types of brain injuries, as far as we know this is the first
30 time that these neuroprotetive effects of PEA are observed in a neonatal AI model. Overall, these
31 results indicate that PEA could be a good candidate to focus on in further studies related to AI, a
32 traumatic and not so uncommon event for which effective treatments are lacking.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1
2 Ahmad A, Genovese T, Impellizzeri D, Crupi R, Velardi E, Marino A, Esposito E, Cuzzocrea S (2012)
3
4 Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle
5
6 cerebral artery occlusion in rats. *Brain Res* 1477:45-58. <https://doi.org/10.1016/j.brainres.2012.08.006>
7

8
9 Ahmad T, Laviolette SR (2017) Cannabinoid reward and aversion effects in the posterior ventral
10
11 tegmental area are mediated through dissociable opiate receptor subtypes and separate amygdalar
12
13 and accumbal dopamine receptor substrates. *Psychopharmacology (Berl)* 234:2325-2336.
14
15 <https://doi.org/10.1007/s00213-017-4669-7>
16

17
18 Almlı CR, Levy TJ, Han BH, Shah AR, Gidday JM, Holtzman DM (2000) BDNF protects against
19
20 spatial memory deficits following neonatal hypoxia-ischemia. *Exp Neurol* 166:99-114.
21
22 <https://doi.org/10.1006/exnr.2000.7492>
23

24
25 Alonso-Alconada D, Alvarez A, Hilario E (2011) Cannabinoid as a neuroprotective strategy in
26
27 perinatal hypoxic-ischemic injury. *Neurosci Bull* 27:275-285. [https://doi.org/10.1007/s12264-011-](https://doi.org/10.1007/s12264-011-1008-6)
28
29 1008-6
30

31
32 Balduini W, De Angelis V, Mazzoni E, Cimino M (2000) Long-lasting behavioral alterations following a
33
34 hypoxic/ischemic brain injury in neonatal rats. *Brain Res* 859:318-325. [https://doi.org/10.1016/S0006-](https://doi.org/10.1016/S0006-8993(00)01997-1)
35
36 8993(00)01997-1
37

38
39 Barros CA, Ekuni R, Moro MA, Pereira FM, Dos Santos Pereira MA, Milani H (2009) The cognitive
40
41 and histopathological effects of chronic 4-vessel occlusion in rats depend on the set of vessels
42
43 occluded and the age of the animals. *Behav Brain Res* 197:378-387.
44
45 <https://doi.org/10.1016/j.bbr.2008.10.023>
46

47
48 Bhateja DK, Dhull DK, Gill A, Sidhu A, Sharma S, Reddy BV, Padi SS (2012) Peroxisome proliferator-
49
50 activated receptor- α activation attenuates 3-nitropropionic acid induced behavioral and biochemical
51
52 alterations in rats: possible neuroprotective mechanisms. *Eur J Pharmacol* 674:33-43.
53
54 <https://doi.org/10.1016/j.ejphar.2011.10.029>
55

56
57 Blanco E, Galeano P, Holubiec MI, Romero JI, Logica T, Rivera P, Pavón FJ, Suarez J, Capani F,
58
59 Rodríguez de Fonseca F (2015) Perinatal asphyxia results in altered expression of the hippocampal
60
61
62
63
64
65

1 acylethanolamide/endocannabinoid signaling system associated to memory impairments in
2 postweaned rats. *Front Neuroanat* 9:141. <https://doi.org/10.3389/fnana.2015.00141>
3

4 Blanco-Calvo E, Rivera P, Arrabal S, Vargas A, Pavón FJ, Serrano A, Castilla-Ortega E, Galeano P,
5 Rubio L, Suárez J, Rodríguez de Fonseca F (2014) Pharmacological blockade of either cannabinoid
6 CB1 or CB2 receptors prevents both cocaine-induced conditioned locomotion and cocaine-induced
7 reduction of cell proliferation in the hippocampus of adult male rat. *Front Integr Neurosci* 7:106.
8 <https://doi.org/10.3389/fnint.2013.00106>
9

10 Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart
11 JC, Bastide M (2006) PPAR: a new pharmacological target for neuroprotection in stroke and
12 neurodegenerative diseases. *Biochem Soc Trans* 34:1341-1346. <https://doi.org/10.1042/BST0341341>
13

14 Carrera JM (2006) *Protocolos de Obstetricia y Medicina Perinatal del Instituto Dexeus*. Elsevier
15 Masson, Barcelona
16

17 Cechetti F, Worm PV, Pereira LO, Siqueira IR, A Netto C (2010) The modified 2VO ischemia protocol
18 causes cognitive impairment similar to that induced by the standard method, but with a better survival
19 rate. *Braz. J Med Biol Res* 43:1178-1183. <https://doi.org/10.1590/S0100-879X2010007500124>
20

21 Chen D, Dixon BJ, Doycheva DM, Li B, Zhang Y, Hu Q, He Y, Guo Z, Nowrangi D, Flores J, Filippov
22 V, Zhang JH, Tang J (2018) IRE1 α inhibition decreased TXNIP/NLRP3 inflammasome activation
23 through miR-17-5p after neonatal hypoxic-ischemic brain injury in rats. *J Neuroinflammation* 15:32.
24 <https://doi.org/10.1186/s12974-018-1077-9>.
25

26 Crews FT, Walter TJ, Coleman LG Jr, Vetreno RP (2017) Toll-like receptor signaling and stages of
27 addiction. *Psychopharmacology (Berl)* 234:1483-1498. <https://doi.org/10.1007/s00213-017-4560-6>
28

29 Cristiano L, Cimini A, Moreno S, Ragnelli AM, Paola Cerù M (2005). Peroxisome proliferator-activated
30 receptors (PPARs) and related transcription factors in differentiating astrocyte cultures. *Neuroscience*
31 131:577-587. <https://doi.org/10.1016/j.neuroscience.2004.11.008>
32

33 Cunha-Rodrigues MC, Balduci CTDN, Tenório F, Barradas PC (2018) GABA function may be related
34 to the impairment of learning and memory caused by systemic prenatal hypoxia-ischemia. *Neurobiol*
35 *Learn Mem* 149:20-27. <https://doi.org/10.1016/j.nlm.2018.01.004>
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 D'Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A (2012) Palmitoylethanolamide
2 protects against the amyloid- β 25-35-induced learning and memory impairment in mice, an
3 experimental model of Alzheimer disease. *Neuropsychopharmacology* 37:1784-1792.
4 <https://doi.org/10.1038/npp.2012.25>
5
6

7
8
9 Dai C, Liu Y, Dong Z (2017) Tanshinone I alleviates motor and cognitive impairments via suppressing
10 oxidative stress in the neonatal rats after hypoxic-ischemic brain damage. *Mol Brain* 10:52.
11 <https://doi.org/10.1186/s13041-017-0332-9>
12
13

14
15 Davies M, Jacobs A, Brody DL, Friess SH (2018) Delayed hypoxemia after traumatic brain injury
16 exacerbates long-term behavioral deficits. *J Neurotrauma* 35:790-801.
17 <https://doi.org/10.1089/neu.2017.5354>
18
19

20
21
22 Deacon RM, Bannerman DM, Kirby BP, Croucher A, Rawlins JN (2002) Effects of cytotoxic
23 hippocampal lesions in mice on a cognitive test battery. *Behav Brain Res* 133:57-68.
24 [https://doi.org/10.1016/S0166-4328\(01\)00451-X](https://doi.org/10.1016/S0166-4328(01)00451-X)
25
26

27
28
29 Di Marzo V, Skaper SD (2013) Palmitoylethanolamide: biochemistry, pharmacology and therapeutic
30 use of a pleiotropic anti-inflammatory lipid mediator. *CNS Neurol Disord Drug Targets* 12:4-6.
31 <https://doi.org/10.2174/1871527311312010004>
32
33

34
35
36 Domnick NK, Gretenkord S, De Feo V, Sedlacik J, Brockmann MD, Hanganu-Opatz IL (2015)
37 Neonatal hypoxia-ischemia impairs juvenile recognition memory by disrupting the maturation of
38 prefrontal-hippocampal networks. *Exp Neurol* 273:202-214.
39 <https://doi.org/10.1016/j.expneurol.2015.08.017>
40
41

42
43
44 Driscoll DJO, Felice VD, Kenny LC, Boylan GB, O'Keefe GW (2018) Mild prenatal hypoxia-ischemia
45 leads to social deficits and central and peripheral inflammation in exposed offspring. *Brain Behav*
46 *Immun*, in press. <https://doi.org/10.1016/j.bbi.2018.01.001>
47
48

49
50
51 Ennaceur A (2010) One-trial object recognition in rats and mice: methodological and theoretical
52 issues. *Behav Brain Res* 215:244-254. <https://doi.org/10.1016/j.bbr.2009.12.036>
53
54

55
56 Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1:
57 behavioral data. *Behav Brain Res* 31:47-59. [https://doi.org/10.1016/0166-4328\(88\)90157-X](https://doi.org/10.1016/0166-4328(88)90157-X)
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Esposito E, Impellizzeri D, Mazzon E, Paterniti I, Cuzzocrea S (2012) Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. *PLoS One* 7:e41880. <https://doi.org/10.1371/journal.pone.0041880>

Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleyethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. *Nature* 425:90-93. <https://doi.org/10.1038/nature01921>

Galeano P, Blanco E, Logica Tornatore TM, Romero JI, Holubiec MI, Rodríguez de Fonseca F, Capani F (2015) Life-long environmental enrichment counteracts spatial learning, reference and working memory deficits in middle-aged rats subjected to perinatal asphyxia. *Front Behav Neurosci* 8:406. <https://doi.org/10.3389/fnbeh.2014.00406>

Galeano P, Blanco Calvo E, Madureira de Oliveira D, Cuenya L, Kamenetzky GV, Mustaca AE, Barreto GE, Giraldez-Alvarez LD, Milei J, Capani F (2011) Long-lasting effects of perinatal asphyxia on exploration, memory and incentive downshift. *Int J Dev Neurosci* 29:609-619. <https://doi.org/10.1016/j.ijdevneu.2011.05.002>

Galinsky R, Lear CA, Dean JM, Wassink G, Dhillon SK, Fraser M, Davidson JO, Bennet L, Gunn AJ (2018) Complex interactions between hypoxia-ischemia and inflammation in preterm brain injury. *Dev Med Child Neurol* 60:126-133. <https://doi.org/10.1111/dmcn.13629>

Griva M, Lagoudaki R, Touloumi O, Nousiopoulou E, Karalis F, Georgiou T, Kokaraki G, Simeonidou C, Tata DA, Spandou E (2017) Long-term effects of enriched environment following neonatal hypoxia-ischemia on behavior, BDNF and synaptophysin levels in rat hippocampus: effect of combined treatment with G-CSF. *Brain Res* 1667:55-67. <https://doi.org/10.1016/j.brainres.2017.05.004>

Halliwell B (1992) Reactive oxygen species and the central nervous system. *J Neurochem* 59:1609-1623. <https://doi.org/10.1111/j.1471-4159.1992.tb10990.x>

Hansen HS, Diep TA (2009) N-acylethanolamines, anandamide and food intake. *Biochem Pharmacol* 78:553-560. <https://doi.org/10.1016/j.bcp.2009.04.024>

Holubiec MI, Romero JI, Blanco E, Tornatore TL, Suarez J, Rodríguez de Fonseca F, Galeano P, Capani F (2017) Acylethanolamides and endocannabinoid signaling system in dorsal striatum of rats

1 exposed to perinatal asphyxia. *Neurosci Lett* 653:269-275.
2 <https://doi.org/10.1016/j.neulet.2017.05.06828579484>
3
4 Kumar A, Gupta A, Talukdar B (2007) Clinico-etiological and EEG profile of neonatal seizures. *Indian*
5 *J Pediatr* 74:33-37. <https://doi.org/10.1007/s12098-007-0023-0>
6
7
8
9 Liaury K, Miyaoka T, Tsumori T, Furuya M, Hashioka S, Wake R, Tsuchie K, Fukushima M, Limoa E,
10 Tanra AJ, Horiguchi J (2014) Minocycline improves recognition memory and attenuates microglial
11 activation in Gunn rat: a possible hyperbilirubinemia-induced animal model of schizophrenia. *Prog*
12 *Neuropsychopharmacol Biol Psychiatry* 50:184-190. <https://doi.org/10.1016/j.pnpbp.2013.12.017>
13
14
15 López-Aguilera F, Plateo-Pignatari MG, Biaggio V, Ayala C, Seltzer AM (2012) Hypoxic
16 preconditioning induces an AT2-R/VEGFR-2(Flk-1) interaction in the neonatal brain microvasculature
17 for neuroprotection. *Neuroscience* 216:1-9. <https://doi.org/10.1016/j.neuroscience.2012.04.070>
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, Pizzolato G, Di Marzo V
3 (2010) Possible anandamide and palmitoylethanolamide involvement in human stroke. *Lipids Health*
4 *Dis* 9:47. <https://doi.org/10.1186/1476-511X-9-47>
5

6 Okamoto Y, Tsuboi K, Ueda N (2009) Enzymatic formation of anandamide. *Vitam Horm* 81:1-24.
7
8 [https://doi.org/10.1016/S0083-6729\(09\)81001-7](https://doi.org/10.1016/S0083-6729(09)81001-7)
9

10
11 Pasquarelli N, Porazik C, Hanselmann J, Weydt P, Ferger B, Witting A (2015) Comparative
12 biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord,
13 liver, spleen, fat and muscle tissue. *Neuropharmacology* 91:148-156.
14
15 <https://doi.org/10.1016/j.neuropharm.2014.12.001>
16
17

18
19
20 Paxinos G, Watson C (2007) *The Rat Brain in Stereotaxic Coordinates*. Elsevier, Amsterdam
21

22
23 Pei B, Sun J (2018) Pinocembrin alleviates cognition deficits by inhibiting inflammation in diabetic
24 mice. *J Neuroimmunol* 314:42-49. <https://doi.org/10.1016/j.jneuroim.2017.11.006>
25
26

27
28 Pereira LO, Arteni NS, Petersen RC, da Rocha AP, Achaval M, Netto CA (2007) Effects of daily
29 environmental enrichment on memory deficits and brain injury following neonatal hypoxia-ischemia in
30 the rat. *Neurobiol Learn Mem* 87:101-108. <https://doi.org/10.1016/j.nlm.2006.07.003>
31
32

33
34 Petrosino S, Di Marzo V (2017) The pharmacology of palmitoylethanolamide and first data on the
35 therapeutic efficacy of some of its new formulations. *Br J Pharmacol* 174:1349-1365.
36
37 <https://doi.org/10.1111/bph.13580>
38
39

40
41 Romero JI, Hanschmann EM, Gellert M, Eitner S, Holubiec MI, Blanco-Calvo E, Lillig CH, Capani F
42 (2015) Thioredoxin 1 and glutaredoxin 2 contribute to maintain the phenotype and integrity of neurons
43 following perinatal asphyxia. *Biochim Biophys Acta* 1850:1274-1285.
44
45 <https://doi.org/10.1016/j.bbagen.2015.02.015>
46
47

48
49
50 Romero JI, Holubiec MI, Tornatore TL, Rivière S, Hanschmann EM, Kölliker-Frers RA, Tau J, Blanco
51 E, Galeano P, Rodríguez de Fonseca F, Lillig CH, Capani F (2017) Neuronal damage induced by
52 perinatal asphyxia is attenuated by postinjury glutaredoxin-2 administration. *Oxid Med Cell Longev*
53 2017:4162465. <https://doi.org/10.1155/2017/4162465>
54
55
56
57
58
59
60
61
62
63
64
65

1 Salter MW, Stevens B (2017) Microglia emerge as central players in brain disease. *Nat Med* 23:1018-
2 1027. <https://doi.org/10.1038/nm.4397>

3
4 Saraceno GE, Bertolino ML, Galeano P, Romero JI, Garcia-Segura LM, Capani F (2010) Estradiol
5 therapy in adulthood reverses glial and neuronal alterations caused by perinatal asphyxia. *Exp Neurol*
6 223:615-622. <https://doi.org/10.1016/j.expneurol.2010.02.010>

7
8
9
10
11 Saraceno GE, Castilla R, Barreto GE, Gonzalez J, Kölliker-Frers RA, Capani F (2012) Hippocampal
12 dendritic spines modifications induced by perinatal asphyxia. *Neural Plast* 2012:873532.
13
14 <https://doi.org/10.1155/2012/873532>

15
16
17
18 Sayd A, Antón M, Alén F, Caso JR, Pavón J, Leza JC, Rodríguez de Fonseca F, García-Bueno B,
19 Orio L (2014) Systemic administration of oleoylethanolamide protects from neuroinflammation and
20 anhedonia induced by LPS in rats. *Int J Neuropsychopharmacol* 18:pyu111.
21
22 <https://doi.org/10.1093/ijnp/pyu111>

23
24
25
26
27 Schoch H, Huerta MY, Ruiz CM, Farrell MR, Jung KM, Huang JJ, Campbell RR, Piomelli D, Mahler
28 SV (2018) Adolescent cannabinoid exposure effects on natural reward seeking and learning in rats.
29
30 *Psychopharmacology (Berl)* 235:121-134. <https://doi.org/10.1007/s00213-017-4749-8>

31
32
33
34 Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz WR (2008) Endocannabinoids mediate
35 neuroprotection after transient focal cerebral ischemia. *Brain Res* 1240:213-220.
36
37 <https://doi.org/10.1016/j.brainres.2008.09.019>

38
39
40
41 Scuderi C, Bronzuoli MR, Facchinetti R, Pace L, Ferraro L, Broad KD, Serviddio G, Bellanti F,
42 Palombelli G, Carpinelli G, Canese R, Gaetani S, Steardo L Jr, Steardo L, Cassano T (2018)
43 Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple
44 transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective
45 effects. *Transl Psychiatry* 8:32. <https://doi.org/10.1038/s41398-017-0076-4>

46
47
48
49
50
51 Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D,
52 Petrosino S, Iuvone T, Di Marzo V, Steardo L (2011) Palmitoylethanolamide counteracts reactive
53 astrogliosis induced by β -amyloid peptide. *J Cell Mol Med* 15:2664-2274.
54
55 <https://doi.org/10.1111/j.1582-4934.2011.01267.x>

1 Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, Steardo L, Pompili E, Fumagalli
2 L, Campolongo P, Steardo L (2014) Palmitoylethanolamide controls reactive gliosis and exerts
3 neuroprotective functions in a rat model of Alzheimer's disease. *Cell Death Dis* 5:e1419.
4 <https://doi.org/10.1038/cddis.2014.376>
5
6

7
8 Sebetseba KN, Ramdin T, Ballot D (2017) The use of therapeutic hypothermia in neonates with
9 perinatal asphyxia at Charlotte Maxeke Johannesburg academic hospital: a retrospective review. *Ther*
10 *Hypothermia Temp Manag*, in press. <https://doi.org/10.1089/ther.2017.0040>
11
12
13

14
15 Sedláčková N, Krajčiová M, Koprlová R, Ujházy E, Brucknerová I, Mach M (2014) Subchronic
16 perinatal asphyxia increased anxiety- and depression-like behaviors in the rat offspring. *Neuro*
17 *Endocrinol Lett* 35(Suppl 2):214-220.
18
19
20

21
22 Serrano A, Rivera P, Pavon FJ, Decara J, Suárez J, Rodriguez de Fonseca F, Parsons LH (2012)
23 Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid
24 system-related genes in the rat amygdala. *Alcohol Clin Exp Res* 36:984-394.
25
26
27
28 <https://doi.org/10.1111/j.1530-0277.2011.01686.x>
29
30

31 Strackx E, Van den Hove DL, Prickaerts J, Zimmermann L, Steinbusch HW, Blanco CE, Gavilanes
32 AW, Vles JS (2010) Fetal asphyctic preconditioning protects against perinatal asphyxia-induced
33 behavioral consequences in adulthood. *Behav Brain Res* 208:343-351.
34
35
36
37 <https://doi.org/10.1016/j.bbr.2009.11.040>
38
39

40 Takada SH, Motta-Teixeira LC, Machado-Nils AV, Lee VY, Sampaio CA, Polli RS, Malheiros JM,
41 Takase LF, Kihara AH, Covolan L, Xavier GF, Nogueira MI (2016) Impact of neonatal anoxia on adult
42 rat hippocampal volume, neurogenesis and behavior. *Behav Brain Res* 296:331-338.
43
44
45
46 <https://doi.org/10.1016/j.bbr.2015.08.039>
47

48 Ueda N, Tsuboi K, Uyama T (2013) Metabolism of endocannabinoids and related N-
49 acylethanolamines: canonical and alternative pathways. *FEBS J* 280:1874-1894.
50
51
52
53 <https://doi.org/10.1111/febs.12152>
54

55 Xu J, Chavis JA, Racke MK, Drew PD (2006) Peroxisome proliferator-activated receptor-alpha and
56 retinoid X receptor agonists inhibit inflammatory responses of astrocytes. *J Neuroimmunol* 176:95-
57
58
59
60
61
62
63
64
65 [105. https://doi.org/10.1016/j.jneuroim.2006.04.019](https://doi.org/10.1016/j.jneuroim.2006.04.019)

1 Yang LC, Guo H, Zhou H, Suo DQ, Li WJ, Zhou Y, Zhao Y, Yang WS, Jin X (2015) Chronic
2 oleoylethanolamide treatment improves spatial cognitive deficits through enhancing hippocampal
3 neurogenesis after transient focal cerebral ischemia. *Biochem Pharmacol* 94:270-281.
4 <https://doi.org/10.1016/j.bcp.2015.02.012>
5
6

7
8
9 Zhou Y, Schwartz BI, Giza J, Gross SS, Lee FS, Kreek MJ (2017) Blockade of alcohol escalation and
10 "relapse" drinking by pharmacological FAAH inhibition in male and female C57BL/6J mice.
11 *Psychopharmacology (Berl)* 234:2955-2970. <https://doi.org/10.1007/s00213-017-4691-9>
12
13

14
15 Zhou Y, Yang L, Ma A, Zhang X, Li W, Yang W, Chen C, Jin X (2012) Orally administered
16 oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome
17 proliferator-activated receptor α . *Neuropharmacology* 63:242-249.
18
19 <https://doi.org/10.1016/j.neuropharm.2012.03.008>
20
21
22

23
24 Zhu H, Qiao L, Sun Y, Yin L, Huang L, Li J, Jiang L (2018) Basic fibroblast growth factor enhances
25 cell proliferation in the dentate gyrus of neonatal rats following hypoxic-ischemic brain damage.
26 *Neurosci Lett*, in press. <https://doi.org/10.1016/j.neulet.2018.01.046>
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figures legends

Figure 1. Exploratory activity and anxiety-related behaviors in the EPM test. **a)** Distance covered, **b)** Closed arm entries, **c)** Percentage of open arms entries, **d)** Percentage of time in open arms. Locomotor activity was reduced in AI groups. No differences in anxiety-related behaviors were observed between groups. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. Symbols and lines depict the mean \pm SEM of 7-10 rats/group. *** $p < 0.01$.

Figure 2. Exploratory activity and anxiety-related behaviors in the OF test. **a)** Distance covered, **b)** Number of rears, **c)** Entries into the center, **d)** Time in central area. Locomotor activity was reduced in AI groups during their first five minutes of exposition to OF. No differences in anxiety-related behaviors were observed between groups. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. Symbols and lines depict the mean \pm SEM of 7-10 rats/group. * $p < 0.05$ vs. AI groups; ## $p < 0.01$ ### $p < 0.001$ vs. first five minutes.

Figure 3. Palmitoylethanolamide treatment prevents recognition memory impairment associated to neonatal anoxia-ischemia. **a)** Discrimination index (d1) and **b)** discrimination ratio (d2). One sample t-tests: *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ vs. d1 and d2 values expected when both objects (familiar and novel) are explored the same amount of time (0 in both cases). Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. Bars depict the mean \pm SEM of 7-10 rats/group.

Figure 4. Spatial learning in the MWM. **a)** Latency to platform, **b)** Distance to platform, **c)** Swim speed. Latency, distance and swim speed decreased similarly across days of training, indicating that all groups acquired the task at the same rate across days of training. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg,

PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. Symbols and lines depict the mean \pm SEM of 7-10 rats/group.

Figure 5. Spatial reference memory deficit induced by neonatal anoxia-ischemia is prevented by palmitoylethanolamide treatment. **a)** Percentage of time spent in the target quadrant during the probe trial. *** $p < 0.001$, ** $p < 0.01$ vs. percentage of time expected by chance (25 %, dashed line). **b)** Circular area crossing during the probe trial. * $p < 0.05$, ** $p < 0.01$ vs. sham groups and AI-P10 group. Bars depict the mean \pm SEM of 7-10 rats/group. **c)** Contingency plots. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively.

Figure 6. Immunohistochemical expression of Iba-1 in the hippocampus. **a)** Representative photomicrographs of Iba-1 immunostaining in the hippocampus. Scale bars: 15 μ m. (Photomicrographs of sham groups treated with OEA (2 and 10 mg/kg) and PEA (2 and 10 mg/kg) can be found in Fig. S3). **b-d)** Quantification of Iba-1 positive cells across layers of the hippocampus (CA1, CA3 and DG). Bars depict mean \pm SEM of 4-7 sections/rat from groups of 4-5 rats. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively; AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. SO: *Stratum oriens*; SP: *Stratum pyramidale*; SR: *Stratum radiatum*; SL-M: *stratum lacunosum moleculare*; ml: molecular cell layer; gcl: granular cell layer; pcl: polymorphic cell layer. * $p < 0.05$; ** $p < 0.01$ and *** $p < 0.001$ vs. sham-operated groups.

Figure 7. Immunohistochemical expression of GFAP in the hippocampus. **a)** Representative photomicrographs of GFAP immunostaining in the hippocampus. Scale bars: 15 μ m. (Photomicrographs of sham groups treated with OEA (2 and 10 mg/kg) and PEA (2 and 10 mg/kg) can be found in Fig. S4). **b-d)** Quantification of GFAP positive cells across layers of the hippocampus (CA1, CA3 and DG). Bars depict mean \pm SEM of 4-7 sections/rat from groups of 4-5 rats. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively; AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. SO: *Stratum oriens*; SP: *Stratum pyramidale*; SR: *Stratum radiatum*; SL-M: *stratum lacunosum molecular*; ml: molecular cell layer; gcl: granular cell layer; pcl: polymorphic cell layer. * $p < 0.05$; ** $p < 0.01$ and *** $p < 0.001$ vs. sham-operated groups; # $p < 0.05$ vs. AI-P10 group; \$ $p < 0.05$ vs. Sham-Veh group.

Figure 8. Immunohistochemical expression of PPAR α in the hippocampus. a) Representative photomicrographs of PPAR α immunostaining in the hippocampus. Scale bars: 15 μ m. (Photomicrographs of sham groups treated with OEA (2 and 10 mg/kg) and PEA (2 and 10 mg/kg) can be found in Fig. S5). **b-d)** Quantification of PPAR α positive cells across layers of the hippocampus (CA1, CA3 and DG). Bars depict mean \pm SEM of 4-7 sections/rat from groups of 4-5 rats. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively; AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. SO: *Stratum oriens*; SP: *Stratum pyramidale*; SR: *Stratum radiatum*; SL-M: *stratum lacunosum molecular*; ml: molecular cell layer; gcl: granular cell layer; pcl: polymorphic cell layer. ** $p < 0.01$ and *** $p < 0.001$.